- Conditions
- KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Pembrolizumab, Trametinib
- Biological · Drug
- Lead sponsor
- Jonathan Riess
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lung Cancer
- Interventions
- paclitaxel
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Interventions
- Ipilimumab, Placebo, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 33
- States / cities
- San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
- Conditions
- HER2-positive Advanced Solid Tumor
- Interventions
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
- Biological · Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Cerritos, California • Los Angeles, California • San Diego, California + 29 more
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- Stereotactic body RT and IRGA
- Radiation
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Cetuximab, Osimertinib, Tucatinib
- Biological · Drug
- Lead sponsor
- Jonathan Riess
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Recurrent Non Small Cell Lung Cancer
- Interventions
- Itraconazole, Pemetrexed
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- SS1(dsFv)-PE38 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel, erlotinib hydrochloride
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Trabedersen (OT-101)
- Biological · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
- Interventions
- yttrium Y 90-edotreotide
- Radiation
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cancer
- Interventions
- therapeutic autologous lymphocytes
- Biological
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, pemetrexed disodium, docetaxel
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 13
- States / cities
- Detroit, Michigan • New York, New York • Cleveland, Ohio + 3 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Dexamethasone, Device for PET, Laboratory Biomarker Analysis, Positron Emission Tomography
- Drug · Device · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
- Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • The Bronx, New York • Pittsburgh, Pennsylvania
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • The Bronx, New York
- Conditions
- Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
- Interventions
- Levetiracetam (Keppra)
- Drug
- Lead sponsor
- Ayal A. Aizer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts